Literature DB >> 3029336

Peripheral neuropathy in mitochondrial disease.

G Pezeshkpour, C Krarup, F Buchthal, S DiMauro, N Bresolin, J McBurney.   

Abstract

Clinical, electrophysiological, histological and biochemical studies of two patients with mitochondrial disease revealed a moderately advanced axonal neuropathy with mitochondrial paracrystalline inclusions in Schwann cells, fibroblasts and muscle fibers. In addition there was a myopathy, and the activity of muscle cytochrome c oxidase was diminished by more than 50%. There were electrophysiological signs of myopathy, neuropathy and failure of excitation-contraction coupling in both patients. The partial enzyme deficiency raises some questions as to its pathogenetic role in these neuromyopathies.

Entities:  

Mesh:

Year:  1987        PMID: 3029336     DOI: 10.1016/0022-510x(87)90129-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine.

Authors:  L D Lewis; F M Hamzeh; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis.

Authors:  J L Martin; C E Brown; N Matthews-Davis; J E Reardon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  Endocrine involvement in mitochondrial encephalomyopathy with partial cytochrome c oxidase deficiency.

Authors:  C Doriguzzi; L Palmucci; T Mongini; N Bresolin; L Bet; G Comi; R Lala
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

4.  Metabolism, mitochondrial uptake and toxicity of 2', 3'-dideoxycytidine.

Authors:  L Rossi; S Serafini; G F Schiavano; A Casabianca; G Vallanti; L Chiarantini; M Magnani
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

Review 5.  Molecular defects in cytochrome oxidase in mitochondrial diseases.

Authors:  S DiMauro; M Zeviani; R Rizzuto; A Lombes; H Nakase; E Bonilla; A Miranda; E Schon
Journal:  J Bioenerg Biomembr       Date:  1988-06       Impact factor: 2.945

6.  Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults.

Authors:  S A Riddler; L H Wang; J A Bartlett; P M Savina; M V Packard; D K McMahon; M R Blum; J A Dunn; M M Elkins; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 7.  Mitochondrial abnormalities in human sural nerves: fine structural evaluation of cases with mitochondrial myopathy, hereditary and non-hereditary neuropathies, and review of the literature.

Authors:  J M Schröder; C Sommer
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides.

Authors:  D J Medina; C H Tsai; G D Hsiung; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

Review 9.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

10.  5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

Authors:  S M Daluge; D J Purifoy; P M Savina; M H St Clair; N R Parry; I K Dev; P Novak; K M Ayers; J E Reardon; G B Roberts
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.